Apremilast has demonstrated sustained and clinically meaningful improvements in signs and symptoms of PsA, as well as in physical function in patients who continued treatment over 5 years. Apremilast also demonstrated a favourable safety profile and was generally well tolerated at 5 years.
Apremilast is an oral phosphodiesterase 4 inhibitor that inhibits the PDE4 intracellular pathway of inflammatory mediators associated with the pathogenesis of PsA. Long-term efficacy and safety of treatment with apremilast were evaluated for up to 5 years in patients with active PsA by using data from the phase 3 PALACE 1, 2, and 3 studies. Eligible patients had active PsA (duration >6 months, meeting CASPAR criteria, ≥3 SJC, and ≥3 TJC) despite prior conventional treatment with DMARDs and/or biologics.
A total of 1,493 patients were randomised at baseline (1:1:1) to receive placebo, 30 mg apremilast BID, or 20 mg apremilast BID. Placebo subjects were re-randomised 1:1 to 30...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Synergistic Effect NSAIDs plus TNFi in Slowing Radiographic Progression in Ankylosing Spondylitis Patients Next Article
Osteoporosis and Vertebral Fractures Associated with Disease Activity/Radiographic Damage in Axial Spondyloarthritis »
Table of Contents: EULAR 2018
Psoriasis and Psoriatic Arthritis
Osteoporosis and Osteoarthritis
Systemic Sclerosis and Systemic Lupus Erythematosus
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.